- Home
- WYHG vs MNPR Comparison
WYHG vs MNPR Comparison
Compare WYHG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- MNPR
- Stock Information
- Founded
- WYHG 1915
- MNPR 2014
- Country
- WYHG China
- MNPR United States
- Employees
- WYHG 491
- MNPR N/A
- Industry
- WYHG
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- MNPR Health Care
- Exchange
- WYHG NYSE
- MNPR Nasdaq
- Market Cap
- WYHG 261.7M
- MNPR 244.1M
- IPO Year
- WYHG 2024
- MNPR 2019
- Fundamental
- Price
- WYHG $9.13
- MNPR $38.53
- Analyst Decision
- WYHG
- MNPR Strong Buy
- Analyst Count
- WYHG 0
- MNPR 6
- Target Price
- WYHG N/A
- MNPR $49.60
- AVG Volume (30 Days)
- WYHG 353.7K
- MNPR 33.0K
- Earning Date
- WYHG 01-01-0001
- MNPR 05-08-2025
- Dividend Yield
- WYHG N/A
- MNPR N/A
- EPS Growth
- WYHG 10.09
- MNPR N/A
- EPS
- WYHG 0.27
- MNPR N/A
- Revenue
- WYHG $144,231,605.00
- MNPR N/A
- Revenue This Year
- WYHG N/A
- MNPR N/A
- Revenue Next Year
- WYHG N/A
- MNPR N/A
- P/E Ratio
- WYHG $5.05
- MNPR N/A
- Revenue Growth
- WYHG 9.73
- MNPR N/A
- 52 Week Low
- WYHG $3.55
- MNPR $1.72
- 52 Week High
- WYHG $5.35
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- MNPR 53.10
- Support Level
- WYHG N/A
- MNPR $36.80
- Resistance Level
- WYHG N/A
- MNPR $43.00
- Average True Range (ATR)
- WYHG 0.00
- MNPR 6.19
- MACD
- WYHG 0.00
- MNPR 0.19
- Stochastic Oscillator
- WYHG 0.00
- MNPR 49.30
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The company is mainly engaged in offering ready to eat and packaged meat dishes. Its product offerings include supreme crispy sausage, fully thin sausage, Chinese sausage, Dongguan Erba sausage, yellow scorpion sausage, alcohol sausage, and meat chop.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.